ClinicalTrials.Veeva

Menu

CPAP Versus HFNO for the Treatment of Acute Hypoxemic Respiratory Failure Due to Community Acquired Pneumonia

E

Evangelismos Hospital

Status

Enrolling

Conditions

Respiratory Failure
Pneumonia

Treatments

Device: CPAP
Device: HFNO

Study type

Observational

Funder types

Other

Identifiers

NCT05755425
139/05-05-2022

Details and patient eligibility

About

the study compares two non-invasive respiratory support modalities ie CPAP and High Flow nasal cannula oxygen for the treatment of severe hypoxemic respiratory failure attributed to Community acquired Pneumonia.

Full description

CPAP and High Flow nasal cannula oxygen are two established modalities for non-invasive respiratory support . In COVID pandemic era both CPAP and HFNO were widely used in the ward for the treatment of COVID-19 induced acute hypoxemic respiratory failure in order to prevent progression to intubation. Head to head comparison between the two modalities mentioned for the treatment of severe hypoxemic respiratory failure is not available neither in COVID pneumonia or Community acquired pneumonia (CAP).

Enrollment

100 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients with age >18 year old.
  • Been hospitalized with community acquired pneumonia
  • hospitalized in common ward (not ICU)
  • Patients should have pneumonia- pulmonary infiltrates in chest-xray and hypoxemic respiratory failure.
  • Patients should be unable to keep: SpO2>93% with FiO2 50%, or SpO2 95% with FiO2 50% and have evidence of respiratory distress defined as Respiratory rate -RR>35/min

Exclusion criteria

  • Need for immediate or imminent intubation
  • not fit for escalation of treatment: defined as intubation, mechanical ventilation and ICU support.
  • Pregnant women
  • Contraindication to CPAP or HFNO

Trial design

100 participants in 2 patient groups

CPAP
Description:
When a patient needs FiO2 \>50% to keep SpO2 \>93%, or SpO2 \>95% in case of persistent respiratory distress defined as RR\>35/min, full face CPAP will be applied
Treatment:
Device: CPAP
HFNO
Description:
When a patient needs FiO2 \>50% to keep SpO2 \>93%, or SpO2 \>95% in case of persistent respiratory distress defined as RR\>35/min, HFNO will be applied
Treatment:
Device: HFNO

Trial contacts and locations

2

Loading...

Central trial contact

IOANNIS KALOMENIDIS, PhD; IOANNA SIGALA, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems